Abstract
The DNA damage response is crucial for the efficacy of radiotherapy (RT), prompting efforts to target this pathway with radiosensitizers to improve outcomes. Early clinical trials evaluating this approach, however, have failed to yield evidence of benefit in unselected populations. Here we demonstrate that a genotype-directed combination of DNA repair inhibition and RT can unleash the significant therapeutic benefit of this approach in pre-clinical models and present first experience from a Phase I/II trial (NCT05566574) testing this concept. Using CRISPR/Cas9, we created isogenic murine models (Atm-/- and WT) in 4T1 breast and CT26 colorectal cancer models, and then studied the synergy between camonsertib and RT across genotypes. In vitro, camonsertib radio-sensitized both Atm-/- and WT models, but was more potent and synergistic in Atm-/- models. In the orthotopically implanted 4T1 model, the combination of camonsertib (30 mg/kg, 3 days on; 4 days off) with RT (20Gy x 1) significantly delayed tumor growth in Atm-/- tumors compared to WT (p < 0.001; n=10 mice per group). Overall survival (OS) also improved in mice with Atm-/- tumors (20% alive at 150 days) vs. WT (0% alive; p < 0.001; log-rank test). Similar results were observed using other RT dose-fractionations (4Gy x 5 daily, 6Gy x 3, 8Gy x 2) with camonsertib. In the flank-implanted CT26 model, Atm-/- tumors had markedly improved response to combination therapy with 7/8 mice achieving a complete response (CR) compared to only 1/8 WT tumors (p<0.001). OS was also significantly improved with 87% of mice with CT26 Atm-/- tumors cured compared to 0% of CT26 WT tumors (p < 0.001). To evaluate the genotype-specificity for synergy from combination therapy, we performed similar experiments in a 4T1 Brca1-/- model, a key mediator of homologous recombination, and observed an absence of synergy, consistent with our hypothesis. Analysis of the microenvironment of 4T1 Atm-/- treated with combination therapy by flow cytometry did not reveal significant increases in CD4 or CD8 T-cells compared to vehicle nor increases in activated CD8 T-cells (Ki67+, PD1+, or GzmB+) suggesting the therapeutic benefit was primarily mediated by cell intrinsic effects. Similarly, re-challenge experiments in cured mice did not identify strong evidence of immunologic memory, again suggesting a modest immunologic role for efficacy of combination therapy in this setting. Based on these results, we initiated a Phase I/II study of camonsertib with RT (4Gy x 5) in patients with metastatic cancer that require palliative RT and have mutations in ATM (pathogenic or variant of unknown significance). The first two patients with pathogenic ATM mutant tumors enrolled in the Phase I portion of the study have demonstrated metabolic CR to combination therapy on PET scan. Overall, our findings suggest that genotype-directed concurrent radio-sensitization could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments. Further research to test this hypothesis is ongoing.
Citation Format: Victor Ng, Sonali Sinha, Ardijana Novaj, Jennifer Ma, Niamh McDermott, Ana Longhini, Rui Gardner, Ezra Rosen, Simon Powell, Diana Mandelker, Atif Khan, Jeremy Setton, Anne Roulston, Stephen Morris, Maria Koehler, Nancy Lee, Jorge Reis-Filho, Nadeem Riaz. Genotype-directed synthetic cytotoxicity of ATR inhibition with radiotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl):Abstract nr A002.
Need a simple solution for managing your BibTeX entries? Explore CiteDrive!
- Web-based, modern reference management
- Collaborate and share with fellow researchers
- Integration with Overleaf
- Comprehensive BibTeX/BibLaTeX support
- Save articles and websites directly from your browser
- Search for new articles from a database of tens of millions of references
Try out CiteDrive More from our Archive
-
DOI: 10.1158/1940-6207.capr-23-0359 2024
Acceptability of Personalized Lung Cancer Screening Program Among Primary Care Providers
Paul J. Resong, Jiangong Niu, Gabrielle F. Duhon, Lewis E. Foxhall, Sanjay Shete, Robert J. Volk, Iakovos Toumazis
-
DOI: 10.1146/annurev-cancerbio-061421-014236 2024
Next-Generation Therapies for Multiple Myeloma
Erin W. Meermeier, P. Leif Bergsagel, Marta Chesi
-
DOI: 10.1146/annurev-cancerbio-062822-110356 2024
Therapeutic Discovery for Chromatin Complexes: Where Do We Stand?
Dominic D.G. Owens, Matthew E.R. Maitland, Cheryl H. Arrowsmith, Dalia Barsyte-Lovejoy
-
DOI: 10.1146/annurev-cancerbio-062722-012209 2024
Small-Molecule Approaches to Target Transcription Factors
Huarui Cui, Morgan Stilgenbauer, Angela N. Koehler
-
DOI: 10.1200/jco.23.01796 2024
Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy
Matthew J. Ehrhardt, Qi Liu, Daniel A. Mulrooney, Isaac B. Rhea, Stephanie B. Dixon, John T. Lucas, Yadav Sapkota, Kyla Shelton, Kirsten K. Ness, Deo Kumar Srivastava, Aaron McDonald, Leslie L. Robison, Melissa M. Hudson, Yutaka Yasui, Gregory T. Armstrong
-
DOI: 10.1200/po.23.00257 2024
Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma
Ronik Kothari, Sara Kreimer, Helen Nadel, Hilary Seeley, Gary Hartman, Kara D. Meister
-
DOI: 10.1200/po.23.00296 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials
Rachel Woodford, Deborah Zhou, Peey-Sei Kok, Sally J. Lord, Michael Friedlander, Ian Marschner, R. John Simes, Chee Khoon Lee
-
DOI: 10.1200/po.23.00333 2024
Somatic Versus Germline: A Case Series of Three Children With <i>ATM</i>-Mutated Medulloblastoma
Lydia T. Tam, Bonnie Cole, Shannon M. Stasi, Vera A. Paulson, Jason N. Wright, Corrine Hoeppner, Susan Holtzclaw, Erin E. Crotty, Richard G. Ellenbogen, Amy Lee, Ralph P. Ermoian, Christina M. Lockwood, Sarah E.S. Leary, Rebecca Ronsley
-
DOI: 10.1200/po.23.00117 2024
Precision Medicine for Childhood Cancer: Current Limitations and Future Perspectives
Martin G. McCabe, Birgit Geoerger, Louis Chesler, Darren Hargrave, D. Williams Parsons, Cornelis M. van Tilburg, Gudrun Schleiermacher, John A. Hickman, Sally L. George
-
DOI: 10.1200/po.23.00196 2024
Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-Analysis
Robert F. Power, Damien E. Doherty, Imelda Parker, David J. Gallagher, Maeve A. Lowery, Karen A. Cadoo